UB Paderborn / Katalog / Suche / in CDI

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis

Osteoporosis international, 2000, Vol.11 (1), p.83-91

2000

Volltextzugriff (PDF)

Adherence to treatment of osteoporosis : a need for study

Osteoporosis international, 2007-10, Vol.18 (10), p.1311-1317

2007

Volltextzugriff (PDF)

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies

Annals of the Rheumatic Diseases, 2011-10, Vol.70 (10), p.1713-1718

2011

Volltextzugriff (PDF)

Longitudinal study of magnetic resonance imaging and standard X-rays to assess disease progression in osteoarthritis

Osteoarthritis and cartilage, 2007-01, Vol.15 (1), p.98-103

2007

Volltextzugriff (PDF)

68 Regional Differences of Spinal BMD Changes After One Year Once-Monthly Ibandronate as Measured by 3D QCT

Journal of clinical densitometry, 2009, Vol.12 (1), p.120-120

2009

Volltextzugriff (PDF)

Recommendations for the registration of drugs used in the treatment of osteoarthritis

Annals of the rheumatic diseases, 1996-08, Vol.55 (8), p.552-557

1996

Volltextzugriff (PDF)

PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATE

The Lancet (British edition), 1989-12, Vol.334 (8678), p.1469-1471

1989

Volltextzugriff (PDF)

Risedronate reverses bone loss in postmenopausal women with low bone mass : Results from a multinational, double-blind, placebo-controlled trial

The journal of clinical endocrinology and metabolism, 2000-05, Vol.85 (5), p.1895-1900

2000

Volltextzugriff (PDF)

Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis

Bone (New York, N.Y.), 2001, Vol.28 (1), p.108-112

2001

Volltextzugriff (PDF)

Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis

Bone (New York, N.Y.), 2008-08, Vol.43 (2), p.343-347

2008

Volltextzugriff (PDF)

Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis

Osteoarthritis and cartilage, 2004-04, Vol.12 (4), p.263-268

2004

Volltextzugriff (PDF)

Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis

Rheumatology (Oxford, England), 2011-10, Vol.50 (10), p.1732-1736

2011

Volltextzugriff (PDF)

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group

Osteoporosis international, 2000, Vol.11 (1), p.83-91

2000

Volltextzugriff (PDF)

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies

Annals of the rheumatic diseases, 2011, Vol.70 (10), p.1715-1720

2011

Volltextzugriff (PDF)

Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of paget's disease of bone

Journal of bone and mineral research, 1994-05, Vol.9 (5), p.615-619

1994

Volltextzugriff (PDF)

Paget's disease of bone treated with a five day course of oral tiludronate

Annals of the rheumatic diseases, 1993-01, Vol.52 (1), p.54-57

1993

Volltextzugriff (PDF)

Long-lasting dermatological lesions after tiludronate therapy

Calcified tissue international, 1992-04, Vol.50 (4), p.378-380

1992

Volltextzugriff (PDF)

Recommendations for the Registration of Agents to be Used in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Updated Recommendations from the Group for the Respect of Ethics and Excellence in Science

Seminars in arthritis and rheumatism, 2005-08, Vol.35 (1), p.1-4

2005

Volltextzugriff (PDF)

Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group

The journal of clinical endocrinology and metabolism, 2000-05, Vol.85 (5), p.1895

2000

Volltextzugriff (PDF)

Prevention of Postmenopausal Bone Loss by Tiludronate

Obstetrical & gynecological survey, 1990-06, Vol.45 (6), p.385-385

1990

Volltextzugriff (PDF)

Alveolar echinococcosis with spinal localization

La Presse médicale (1983), 1983-05, Vol.12 (21), p.1366

1983

Volltextzugriff (PDF)

Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone : a double blind, multiple-dosage, placebo-controlled study

Arthritis and rheumatism, 1992-08, Vol.35 (8), p.967-974

1992

Volltextzugriff (PDF)

Alveolar echinococcosis with spinal localization

Presse medicale (Paris, France : 1983), 1983, Vol.12 (21), p.1366-1366

1983

Volltextzugriff (PDF)

Prevention of postmenopausal bone loss by tiludronate

International journal of gynecology and obstetrics, 1990-08, Vol.32 (4), p.390-390

1990

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis

Adherence to treatment of osteoporosis : a need for study

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies

Longitudinal study of magnetic resonance imaging and standard X-rays to assess disease progression in osteoarthritis

Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men

68 Regional Differences of Spinal BMD Changes After One Year Once-Monthly Ibandronate as Measured by 3D QCT

Recommendations for the registration of drugs used in the treatment of osteoarthritis

PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATE

Risedronate reverses bone loss in postmenopausal women with low bone mass : Results from a multinational, double-blind, placebo-controlled trial

Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis

Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis

Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis

Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies

Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of paget's disease of bone

Paget's disease of bone treated with a five day course of oral tiludronate

Long-lasting dermatological lesions after tiludronate therapy

Recommendations for the Registration of Agents to be Used in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Updated Recommendations from the Group for the Respect of Ethics and Excellence in Science

Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group

Prevention of Postmenopausal Bone Loss by Tiludronate

Alveolar echinococcosis with spinal localization

Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone : a double blind, multiple-dosage, placebo-controlled study

Alveolar echinococcosis with spinal localization

Prevention of postmenopausal bone loss by tiludronate

Suchergebnisse filtern